Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 457-466

  Wheal, Amanda J ^a   Cipriano, Mariateresa ^c   Fowler, Christopher J ^c   Randall, Michael D ^a   O'Sullivan, Saoirse Elizabeth ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HYDROGEN PEROXIDE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMORAL ARTERY; INCUBATION TIME; ISOLATED HEART; LIMIT OF DETECTION; MALE; MYOGRAPHY; NONHUMAN; RAT; VASCULAR ENDOTHELIUM; VASODILATATION; ZUCKER DIABETIC FATTY RAT; ZUCKER RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACETYLCHOLINE; ANIMALS; CANNABIDIOL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIABETES MELLITUS, TYPE 2; DINOPROSTONE; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; HYDROGEN PEROXIDE; MALE; NITRIC OXIDE; PPAR GAMMA; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SUPEROXIDE DISMUTASE; VASODILATION; VASODILATOR AGENTS;

EID: 84908139899     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217125     Document Type: Article

References (37)

1. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, and Giagnoni G (2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369:294-299.
2. De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, Sarnelli G, Cuomo R, Steardo L, De Man JG, et al. (2011) Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One 6:e28159.
3. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, and Di Marzo V (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168:79-102.
4. Di Marzo V, Piscitelli F, and Mechoulam R (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handbook Exp Pharmacol 203:75-104.
5. Dong L, Vecchio AJ, Sharma NP, Jurban BJ, Malkowski MG, and Smith WL (2011) Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem 286:19035-19046.
6. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, and Liou GI (2006) Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168:235-244.
7. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR, Iuvone T, and Steardo L (2011) Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One 6:e28668.
8. Foadi N, Leuwer M, Demir R, Dengler R, Buchholz V, de la Roche J, Karst M, Haeseler G, and Ahrens J (2010) Lack of positive allosteric modulation of mutated alpha (1) S267I glycine receptors by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381:477-482.
9. Herradón E, Martín MI, and López-Miranda V (2007) Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152:699-708.
10. Horváth B, Mukhopadhyay P, Haskó G, and Pacher P (2012) The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 180:432-442.
11. Kathmann M, Flau K, Redmer A, Tränkle C, and Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372:354-361.
12. Liu B, Luo W, Zhang Y, Li H, Zhu N, Huang D, and Zhou Y (2012) Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol 97:277-289.
13. Liu B, Zhang Y, Zhu N, Li H, Luo W, and Zhou Y (2013) A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries. Am J Physiol Renal Physiol 305:F1315-F1322.
14. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, and Parolaro D (2008) 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104:1091-1100.
15. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, and Takeshita A (2000) Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 106:1521-1530.
16. Meade EA, Smith WL, and DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614.
17. Onnis V, Congiu C, Björklund E, Hempel F, Söderström E, and Fowler CJ (2010) Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. J Med Chem 53:2286-2298.
18. O'Sullivan SE, Kendall DA, and Randall MD (2006) Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 317:428-438.
19. O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, and Kendall DA (2009) Timedependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612:61-68.
20. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, and Randall MD (2005) Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337:824-831.
21. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199-215.
22. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR, Obrosova IG, and Pacher P (2007) Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 293:H610-H619.
23. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L, et al. (2010) Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56:2115-2125.
24. Randall MD, Kendall DA, and O'Sullivan S (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142:20-26.
25. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, and Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126:665-672.
26. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, and Bohlin L (2011) Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull 34:774-778.
27. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, and Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216-221.
28. Stanley C and O'Sullivan SE (2014a) Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol 171:1361-1378.
29. Stanley CP, Hind WH, and O'Sullivan SE (2013a) Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol 75:313-322.
30. Stanley CP and O'Sullivan SE (2014b) Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res 81:74-82.
31. Stanley CP, Wheal AJ, Randall MD, and O'Sullivan SE (2013b) Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. Eur J Pharmacol 720:376-382.
32. Takeda S, Hirayama A, Urata S, Mano N, Fukagawa K, Imamura M, Irii A, Kitajima S, Masuyama T, Nomiyama M, et al. (2011) Cannabidiol-29, 69-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro. Biol Pharm Bull 34:1252-1256.
33. Toth CC, Jedrzejewski NM, Ellis CL, and Frey WH, Jr (2010) Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 6:16.
34. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, and Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109-1111.
35. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, and Gallily R (2006) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39:143-151.
36. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, and Gallily R (2008) Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54:244-249.
37. Yuan C, Sidhu RS, Kuklev DV, Kado Y, Wada M, Song I, and Smith WL (2009) Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers. J Biol Chem 284:10046-10055.